



## **Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference**

July 30, 2024

AUSTIN, Texas, July 30, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 4:00 p.m. EDT in Boston, MA.



A live webcast of the event can be accessed at <https://investors.aileronrx.com/events-presentations/investor-events>. A replay of the webcast will be available for 90 days following the presentation.

### **About Aileron Therapeutics**

Aileron Therapeutics, Inc. is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis. Aileron's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.

### **Investor Relations & Media Contact:**

Argot Partners  
[aileron@argotpartners.com](mailto:aileron@argotpartners.com)  
212-600-1902

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/aileron-therapeutics-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-302208743.html>

SOURCE Aileron Therapeutics, Inc.